I see some discussions on the forum on FGF-1, but not seeing anything in the context of PD.
One of my patients is asking about this for his PD.
It looks like we have some interesting data on this. Has anyone found a reasonable source for it?
It looks as though in the trial it was dosed:
Week 1 and 2: Daily dosing of 450 µg of FGF-1 each day.
Week 3 No dosing; observation and safety/efficacy testing.
Week 4: Daily dosing of the high dose, 900 µg.
Weeks 5-12: No further drug dosing; just follow-up with weekly visits for safety and efficacy monitoring.
This is probably the reason it’s so expensive. Long chain peptides are expensive to make in low volume in the typical Solid-Phase Peptide Synthesis used for research and low volume applications. Not until you get into Liquid-Phase Peptide Synthesis processes does the price start to come down but there are other factors that impact the price of new peptides.